Literature DB >> 21281839

The economics of diabetes prevention.

William H Herman1.   

Abstract

In the United States, the costs associated with diabetes mellitus are increasing. Although people with diabetes comprise less than 6% of the US population, approximately 1 in 5 health care dollars is spent caring for people with diabetes. Healthy lifestyle interventions for the general population and intensive lifestyle and medication interventions for high-risk individuals present opportunities for diabetes prevention. This article describes the costs associated with glucose intolerance and diabetes, the effect of glucose intolerance and diabetes on the quality of life, and the cost-effectiveness of screening and primary prevention interventions for diabetes prevention.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21281839      PMCID: PMC3061284          DOI: 10.1016/j.mcna.2010.11.010

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  40 in total

1.  Influence of BMI on health-related quality of life: comparison between an obese adult cohort and age-matched population norms.

Authors:  Ananthila Anandacoomarasamy; Ian D Caterson; Steven Leibman; Garett S Smith; Phillip N Sambrook; Marlene Fransen; Lyn M March
Journal:  Obesity (Silver Spring)       Date:  2009-04-23       Impact factor: 5.002

2.  Adapting the Diabetes Prevention Program lifestyle intervention for delivery in the community: the YMCA model.

Authors:  Ronald T Ackermann; David G Marrero
Journal:  Diabetes Educ       Date:  2007 Jan-Feb       Impact factor: 2.140

3.  The relationship between body mass index and health-related quality of life: comparing the EQ-5D, EuroQol VAS and SF-6D.

Authors:  T H Sach; G R Barton; M Doherty; K R Muir; C Jenkinson; A J Avery
Journal:  Int J Obes (Lond)       Date:  2006-05-09       Impact factor: 5.095

4.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

Authors:  H C Gerstein; S Yusuf; J Bosch; J Pogue; P Sheridan; N Dinccag; M Hanefeld; B Hoogwerf; M Laakso; V Mohan; J Shaw; B Zinman; R R Holman
Journal:  Lancet       Date:  2006-09-23       Impact factor: 79.321

5.  Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000.

Authors:  A Icks; W Rathmann; B Haastert; A Gandjour; R Holle; J John; G Giani
Journal:  Diabet Med       Date:  2007-03-22       Impact factor: 4.359

6.  Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.

Authors:  J J Caro; D Getsios; I Caro; W S Klittich; J A O'Brien
Journal:  Diabet Med       Date:  2004-11       Impact factor: 4.359

7.  Medical care costs one year after identification of hyperglycemia below the threshold for diabetes.

Authors:  Gregory A Nichols; Bhakti Arondekar; William H Herman
Journal:  Med Care       Date:  2008-03       Impact factor: 2.983

Review 8.  Economic costs of diabetes in the U.S. In 2007.

Authors: 
Journal:  Diabetes Care       Date:  2008-03       Impact factor: 19.112

9.  Complications of dysglycemia and medical costs associated with nondiabetic hyperglycemia.

Authors:  Gregory A Nichols; Bhakti Arondekar; William H Herman
Journal:  Am J Manag Care       Date:  2008-12       Impact factor: 2.229

10.  Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial.

Authors:  Paul Glasziou; Jan Alexander; Elaine Beller; Philip Clarke
Journal:  Health Qual Life Outcomes       Date:  2007-04-27       Impact factor: 3.186

View more
  16 in total

Review 1.  Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction.

Authors:  Matthias Barton; Oliver Baretella; Matthias R Meyer
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

2.  A new approach to integrating patient-generated data with expert knowledge for personalized goal setting: A pilot study.

Authors:  Marissa Burgermaster; Jung H Son; Patricia G Davidson; Arlene M Smaldone; Gilad Kuperman; Daniel J Feller; Katherine Gardner Burt; Matthew E Levine; David J Albers; Chunhua Weng; Lena Mamykina
Journal:  Int J Med Inform       Date:  2020-04-30       Impact factor: 4.046

3.  Delaying progression to type 2 diabetes among high-risk Spanish individuals is feasible in real-life primary healthcare settings using intensive lifestyle intervention.

Authors:  B Costa; F Barrio; J-J Cabré; J-L Piñol; X Cos; C Solé; B Bolíbar; J Basora; C Castell; O Solà-Morales; J Salas-Salvadó; J Lindström; J Tuomilehto
Journal:  Diabetologia       Date:  2012-02-10       Impact factor: 10.122

4.  Can costs of screening for hypertension and diabetes in dental care and follow-up in primary health care be predicted?

Authors:  Sevek Engström; Lars Borgquist; Christian Berne; Lars Gahnberg; Kurt Svärdsudd
Journal:  Ups J Med Sci       Date:  2013-08-19       Impact factor: 2.384

5.  Incidence of type 2 diabetes in pre-diabetic Japanese individuals categorized by HbA1c levels: a historical cohort study.

Authors:  Tetsuya Kawahara; Ryuichiro Imawatari; Chie Kawahara; Tetsuya Inazu; Gen Suzuki
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

6.  Diabetes prevalence and metabolic risk profile in an unselected population visiting pharmacies in Switzerland.

Authors:  Alexandre Rey; Martin Thoenes; Rolf Fimmers; Christoph A Meier; Peter Bramlage
Journal:  Vasc Health Risk Manag       Date:  2012-09-21

7.  The DIAMIND study: postpartum SMS reminders to women who have had gestational diabetes mellitus to test for type 2 diabetes: a randomised controlled trial - study protocol.

Authors:  Emer Heatley; Philippa Middleton; William Hague; Caroline Crowther
Journal:  BMC Pregnancy Childbirth       Date:  2013-04-12       Impact factor: 3.007

8.  Association of enrolment in primary care networks with diabetes care and outcomes among First Nations and low-income Albertans.

Authors:  David J T Campbell; Paul E Ronksley; Brenda R Hemmelgarn; Jianguo Zhang; Cheryl Barnabe; Marcello Tonelli; Braden Manns
Journal:  Open Med       Date:  2012-12-11

9.  Using observational data to inform the design of a prospective effectiveness study for a novel insulin delivery device.

Authors:  Michael Grabner; Yong Chen; Matthew Nguyen; Scott D Abbott; Ralph Quimbo
Journal:  Clinicoecon Outcomes Res       Date:  2013-09-23

10.  Rationale and design of Diabetes Prevention with active Vitamin D (DPVD): a randomised, double-blind, placebo-controlled study.

Authors:  Tetsuya Kawahara; Gen Suzuki; Tetsuya Inazu; Shoichi Mizuno; Fumiyoshi Kasagi; Yosuke Okada; Yoshiya Tanaka
Journal:  BMJ Open       Date:  2016-07-07       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.